|
|
Post by mikesmilitaria on Dec 18, 2016 17:31:01 GMT -5
So SNY is going to allow Lantus generics to destroy their diabetes market status/share and since they have practically nothing in their RX funnel for the future, SNY will allow lack of innovation to complete the destructive course?
I think not. I think they know where their future is in order to maintain and enhance market share in diabetes and implant new tech platforms for the future. Don't let all the head fakes take your eyes off the prize.
|
|
|
|
Post by mikesmilitaria on Dec 18, 2016 17:31:33 GMT -5
NO....Hell NO!
|
|
|
|
Post by drman7 on Dec 19, 2016 11:55:14 GMT -5
Again, Sanofi did not handle the spirometer issue very well and were unprepared which to me was the main issue of not getting the drug in the hands of doctors. Then there is the titration which MNKD tweaked and is tweaking as they go along. SNY did not do anything in regards to improving education in titration, NADA, Zilch. Toujeo, was the main focus for the sales force at SNY which now lead them to layoff over 900. The Irony of things. Imagine if SNY would have tried harder to push Afrezza, maybe those sales folks would still have a job. You never now. Remember chain of command comes from the top, the sales rep did what they were told and they needed to meet there quota to get paid. Afrezza was not selling fast enough so why sell it if Toujeo (they owned) is out (FDA Approved 2/2015). SNY did not see the bigger picture.
|
|
|
|
Post by dreamboatcruise on Dec 19, 2016 16:12:56 GMT -5
Anyone besides me thinking 2017 will be tougher for mannkind than 2016 even was? All the bears are thinking that. All the bulls are thinking it will be much better! :-) And the reptiles are simply confused and have no clue what the future will bring  |
|
